Dyslipidemia Secondary to Hypothyroidism and Cholestasis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944 |
Resumo: | In about 28% of patients, dyslipidemia has a secondary cause. Many times, the treatment of these causes can lead to the total correction of dyslipidemia. We describe the case of a 50-year-old female patient with class II obesity and primary biliary cirrhosis, evaluated for mixed dyslipidemia with poor control (statins and fibrates were being administered) as well as abnormal liver tests. The investigation carried out revealed primary auto-immune hypothyroidism. After normalisation of thyroid function by treatment with levothyroxine, as well as suspending the administration of statins and fibrates, there was an improvement in the lipid profile, although hypercholesterolemia continued. During this time, the patient was diagnosed with diabetes and she re-commenced statin therapy (atorvastatin 10 mg), which resulted in a normal lipid profile being achieved. In this case, the authors set out to highlight the importance of excluding secondary causes of dyslipidemia - including hypothyroidism, and then go on to discuss particular aspects of statin therapy for liver disease. |
id |
RCAP_2a7720590aba94770764753cd3449c7c |
---|---|
oai_identifier_str |
oai:ojs.www.actamedicaportuguesa.com:article/9944 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Dyslipidemia Secondary to Hypothyroidism and CholestasisDislipidemia Secundária a Hipotiroidismo e ColestaseCholestasisDyslipidemiasHypothyroidismLiver CirrhosisBiliaryCirrose Hepática BiliarColestaseDislipidemiasHipotiroidismoIn about 28% of patients, dyslipidemia has a secondary cause. Many times, the treatment of these causes can lead to the total correction of dyslipidemia. We describe the case of a 50-year-old female patient with class II obesity and primary biliary cirrhosis, evaluated for mixed dyslipidemia with poor control (statins and fibrates were being administered) as well as abnormal liver tests. The investigation carried out revealed primary auto-immune hypothyroidism. After normalisation of thyroid function by treatment with levothyroxine, as well as suspending the administration of statins and fibrates, there was an improvement in the lipid profile, although hypercholesterolemia continued. During this time, the patient was diagnosed with diabetes and she re-commenced statin therapy (atorvastatin 10 mg), which resulted in a normal lipid profile being achieved. In this case, the authors set out to highlight the importance of excluding secondary causes of dyslipidemia - including hypothyroidism, and then go on to discuss particular aspects of statin therapy for liver disease.Cerca de 28% dos doentes com dislipidemia apresentam na sua etiologia causas secundárias. A resolução de algumas destas causas pode levar à correção total da dislipidemia. Descreve-se o caso de uma doente do sexo feminino, 50 anos, com obesidade grau II e cirrose biliar primária referenciada por dislipidemia mista com mau controlo (sob estatina e fibrato) e com alterações analíticas hepáticas. No estudo efetuado constatou-se hipotiroidismo primário auto-imune. Após normalização da função tiroideia pelo tratamento com levotiroxina, além da suspensão da estatina e fibrato, verificou-se melhoria do perfil lipídico, embora mantendo hipercolesterolemia. Neste período de tempo foi-lhe diagnosticada diabetes mellitus pelo que se instituiu de novo terapêutica com estatina (atorvastatina 10 mg), com normalização do perfil lipídico. Com este caso pretende-se salientar a importância da exclusão de causas secundárias de dislipidemia, nomeadamente o hipotiroidismo, bem como discutir aspectos particulares do tratamento com estatinas na doença hepática.Ordem dos Médicos2020-03-02info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/mswordimage/jpeghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944oai:ojs.www.actamedicaportuguesa.com:article/9944Acta Médica Portuguesa; Vol. 33 No. 3 (2020): March; 204-207Acta Médica Portuguesa; Vol. 33 N.º 3 (2020): Março; 204-2071646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944/5891https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944/5890https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944/9820https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944/9821https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944/9822https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944/10182https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944/11016Direitos de Autor (c) 2020 Acta Médica Portuguesainfo:eu-repo/semantics/openAccessSaavedra, AnaRodrigues, ElisabeteCarvalho, Davide2022-12-20T11:05:51Zoai:ojs.www.actamedicaportuguesa.com:article/9944Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:19:46.644222Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Dyslipidemia Secondary to Hypothyroidism and Cholestasis Dislipidemia Secundária a Hipotiroidismo e Colestase |
title |
Dyslipidemia Secondary to Hypothyroidism and Cholestasis |
spellingShingle |
Dyslipidemia Secondary to Hypothyroidism and Cholestasis Saavedra, Ana Cholestasis Dyslipidemias Hypothyroidism Liver Cirrhosis Biliary Cirrose Hepática Biliar Colestase Dislipidemias Hipotiroidismo |
title_short |
Dyslipidemia Secondary to Hypothyroidism and Cholestasis |
title_full |
Dyslipidemia Secondary to Hypothyroidism and Cholestasis |
title_fullStr |
Dyslipidemia Secondary to Hypothyroidism and Cholestasis |
title_full_unstemmed |
Dyslipidemia Secondary to Hypothyroidism and Cholestasis |
title_sort |
Dyslipidemia Secondary to Hypothyroidism and Cholestasis |
author |
Saavedra, Ana |
author_facet |
Saavedra, Ana Rodrigues, Elisabete Carvalho, Davide |
author_role |
author |
author2 |
Rodrigues, Elisabete Carvalho, Davide |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Saavedra, Ana Rodrigues, Elisabete Carvalho, Davide |
dc.subject.por.fl_str_mv |
Cholestasis Dyslipidemias Hypothyroidism Liver Cirrhosis Biliary Cirrose Hepática Biliar Colestase Dislipidemias Hipotiroidismo |
topic |
Cholestasis Dyslipidemias Hypothyroidism Liver Cirrhosis Biliary Cirrose Hepática Biliar Colestase Dislipidemias Hipotiroidismo |
description |
In about 28% of patients, dyslipidemia has a secondary cause. Many times, the treatment of these causes can lead to the total correction of dyslipidemia. We describe the case of a 50-year-old female patient with class II obesity and primary biliary cirrhosis, evaluated for mixed dyslipidemia with poor control (statins and fibrates were being administered) as well as abnormal liver tests. The investigation carried out revealed primary auto-immune hypothyroidism. After normalisation of thyroid function by treatment with levothyroxine, as well as suspending the administration of statins and fibrates, there was an improvement in the lipid profile, although hypercholesterolemia continued. During this time, the patient was diagnosed with diabetes and she re-commenced statin therapy (atorvastatin 10 mg), which resulted in a normal lipid profile being achieved. In this case, the authors set out to highlight the importance of excluding secondary causes of dyslipidemia - including hypothyroidism, and then go on to discuss particular aspects of statin therapy for liver disease. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-03-02 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944 oai:ojs.www.actamedicaportuguesa.com:article/9944 |
url |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944 |
identifier_str_mv |
oai:ojs.www.actamedicaportuguesa.com:article/9944 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944/5891 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944/5890 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944/9820 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944/9821 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944/9822 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944/10182 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944/11016 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2020 Acta Médica Portuguesa info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2020 Acta Médica Portuguesa |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf application/pdf application/pdf application/msword image/jpeg |
dc.publisher.none.fl_str_mv |
Ordem dos Médicos |
publisher.none.fl_str_mv |
Ordem dos Médicos |
dc.source.none.fl_str_mv |
Acta Médica Portuguesa; Vol. 33 No. 3 (2020): March; 204-207 Acta Médica Portuguesa; Vol. 33 N.º 3 (2020): Março; 204-207 1646-0758 0870-399X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130647691788288 |